ArticleInternational journal of nanomedicine2013
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- Targeting Drug-Tolerant Persister Cancer Cells: Can Nanomaterial-Based Strategies Be Helpful for Anti-DTP Therapies?Pharmaceutics · 2025Review
- Nano-biomaterials in cancer therapy: Advances in targeting and overcoming cancer stem cell resistance.ADMET & DMPK · 2025Review
- Innovative nanoparticle-based therapeutic strategies against glioblastoma multiform: a focus on enhanced delivery systems and efficacy.Frontiers in bioengineering and biotechnology · 2025Review
- Gold Nanoparticles: Tunable Characteristics and Potential for Nasal Drug Delivery.Pharmaceutics · 2024Article
- Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects.Frontiers in oncology · 2023Review
- Modernistic and Emerging Developments of Nanotechnology in Glioblastoma-Targeted Theranostic Applications.International journal of molecular sciences · 2022Review
- Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.Theranostics · 2022Review
- Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy.CNS oncology · 2019Review
- Current promising treatment strategy for glioblastoma multiform: A review.Oncology reviews · 2019Article
- Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.International journal of nanomedicine · 2018Review
- Antitumor activity of intratracheal inhalation of temozolomide (TMZ) loaded into gold nanoparticles and/or liposomes against urethane-induced lung cancer in BALB/c mice.Drug delivery · 2017Article
- The new era of nanotechnology, an alternative to change cancer treatment.Drug design, development and therapy · 2017Review
- Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma.Current neuropharmacology · 2017Review
- Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy.Frontiers in pharmacology · 2017Review
- Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles.Targeted oncology · 2016Review
- Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy.Frontiers in pharmacology · 2016Review
- Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.International journal of nanomedicine · 2016Article
- Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.Neuro-oncology · 2015Review
- Phytofabrication of bioinduced silver nanoparticles for biomedical applications.International journal of nanomedicine · 2015Article
- Nanopharmacology in translational hematology and oncology.International journal of nanomedicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The low rate of survival for patients diagnosed with glioblastoma may be attributed to the existence of a subpopulation of cancer stem cells. These stem cells have certain properties that enable them to resist chemotherapeutic agents and ionizing radiation. Herein, we show that temozolomide-loaded gold nanostructures are efficient in reducing chemoresistance and destroy 82.7% of cancer stem cells compared with a 42% destruction rate using temozolomide alone. Measurements of in vitro cytotoxicity and apoptosis indicate that combination with gold facilitated the ability of temozolomide, an alkylating drug, to alter the resistance of these cancer stem cells, suggesting a new chemotherapy strategy for patients diagnosed with inoperable recurrent malignant glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.